Cardiologists Hail Stats on Standards, Stents, and Statins

By McCann, Jean | Drug Topics, April 15, 2002 | Go to article overview
Save to active project

Cardiologists Hail Stats on Standards, Stents, and Statins

McCann, Jean, Drug Topics

The rules governing which cardiac patients should get what therapy seem to be changing, based on the results of studies reported at the annual meeting of the American College of Cardiology (ACC), held in Atlanta last month. Another reason for change is the recent revision of some ACC/American Heart Association (AHA) guidelines dealing specifically with the treatment of patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).

One thing that stood out clearly, too, is that many patients who could benefit are not now getting optimal therapy, according to Duke University researcher Eric Peterson, M.D. He reported that only 25% of patients with acute coronary syndromes are receiving glycoprotein (GP) IIb/IIIa inhibitors, which have been shown to reduce the incidence of heart attacks, strokes, and other problems in many high-risk patients. He based this conclusion on a study by the National Registry of Myocardial Infarction, which found that of the 186,727 patients registered, 60,770 were eligible for this class of drugs, but only a quarter had gotten them.

Also, a so-called Crusade initiative, which involved the study in 80 hospitals of physician practices, showed that only 36% of patients were getting the GP IIb/IIa inhibitors, which are recommended to be given to patients within 24 hours of their arrival in the emergency room.

At the same time, however, the new ACC/AHA guidelines call for the use of the inhibitor abciximab (ReoPro, Lilly) only in patients having invasive procedares, such as balloon angioplasty or stenting. The use of two other GP IIb/IIIa inhibitors, eptifibatide (Integrilin injection, Millennium Pharmaceuticals) and tirofiban (Aggrastat injection, Merck), should be confined to high-risk patients who will be treated with medication only, according to the new guidelines drawn up by an expert panel headed by Eugene Braunwald, M.D., Distinguished Hersey Professor of Medicine at Harvard Medical School. As he put it, "We've learned more in a year about unstable angina and NSTEMI than we did in the preceding 20 years."

The new guidelines also recommend adding clopidogrel (Plavix, Bristol-Myers Squibb) to standard therapy, including aspirin, for the acute and continued treatment of unstable angina and mild heart attacks. The Food & Drug Administration recently approved clopidogrel for this purpose.

Meanwhile, at the ACC convention, one study indicated that there is something better than the ACC/AHA guidelines, which called for the use of unfractionated heparin with eptifibatide. Rather, the study, called INTERACT (Integrilin and Enoxaparin Randomized Assessment of Acute Coronary syndrome Treatment), showed that patients receiving a combination of eptifibatide plus the low molecular weight heparin enoxaparin sodium (Lovenox injection, Aventis) experienced a 44% reduction in the risk of heart attack or death compared with patients receiving eptifibatide plus unfractionated heparin, which was the standard. The newer combination was also associated with a 44% decrease in ischemia and a reduced incidence of major bleeding.

All the studies presented at the ACC meeting also highlighted what has become increasingly evident-that each patient is an individual, and not all will benefit from the same drugs. Indeed some patients, according to reports presented at the meeting, would benefit more from expensive implanted $20,000 devices than they would from drugs. Still, it is pharmacotherapy that is the mainstay of the treatment of cardiovascular disease, and below are some of the highlights from this year's ACC meeting:

* Is blocking two enzymes better than one? OVERTURE (Omapatrilat vs. Enalapril Randomized Trial of Utility in Reducing Events) had a combined endpoint of all-cause mortality or hospitalization for heart failure, and randomized 5,770 patients to either the standard ACE inhibitor enalapril or to omapatrilat (Vanlev, Bristol-Myers Squibb), a novel agent that inhibits neutral endopeptidase (NEP)/ angiotensin-converting enzyme (ACE), according to Milton Packer, M.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)


1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25,

Cited article

Cardiologists Hail Stats on Standards, Stents, and Statins


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25,

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.